Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ADAdaptimmune Therapeutics plc logo

Adaptimmune Therapeutics plc (ADAP)

NASDAQ Global Select · Currency in USD
$0.05 ▼ 0.00 (-3.00%)
At close: Nov 21, 9:30 AM ET. Market closed.

Summary

Previous Close
$0.05
Open
$0.04
Day's Range
$0.04 – $0.06
52 Week Range
$0.02 – $0.86
Volume
1,676,117
Avg. Volume
110,644,691
Market Cap
$75.16M
Beta (5Y Monthly)
2.49
PE Ratio (TTM)
--
EPS (TTM)
-$0.28
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$2.83

Profile: Adaptimmune Therapeutics plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
506
CEO
Adrian G. Rawcliffe

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.

Earnings

DateEst.Actual
Nov 12, 2025-$0.09-$0.07Beat
Aug 14, 2025-$0.15-$0.11Beat
May 13, 2025-$0.09-$0.18Miss
Mar 20, 2025-$0.17-$0.26Miss
Nov 13, 2024-$0.17-$0.07Beat
Aug 12, 2024-$0.07$0.24Beat

Analyst view

Consensus price target
$2.83 ▲ +5,735.1%
Range $1.00 – $4.00
Rating: Buy
Buy 56% · Hold 25% · Sell 19%

Get free alerts on ADAP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.